Actively Recruiting

Age: 20Years - 45Years
FEMALE
Healthy Volunteers
NCT03144648

PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women

Led by International Agency for Research on Cancer · Updated on 2025-05-06

3000

Participants Needed

13

Research Sites

689 weeks

Total Duration

On this page

Sponsors

I

International Agency for Research on Cancer

Lead Sponsor

U

University of Chile

Collaborating Sponsor

AI-Summary

What this Trial Is About

Breast cancer has become a major public health problem in Latin America, as it is the most common form of cancer among women. Women are more likely to develop breast cancer at younger age, and to be diagnosed at an advanced stage compared to western women. Over the past twenty years, the mortality from breast cancer in Latin America has also been increasing very rapidly, and is currently the leading cause of cancer mortality. Little is known on specific risk factors for premenopausal breast cancer in general, and in Latin America in particular. There is a lack of specific knowledge on tumor molecular and pathological characteristics of breast cancer in Latin America premenopausal women, and this has major consequences on cancer treatment and survival. To improve our understanding on determinants of breast cancer incidence and mortality in young Latin America women and support preventive actions, we implemented an international, population-based multi-center study in Latin America: the PRECAMA study (Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a multicenter population-based case-control study). PRECAMA is coordinated by the International Agency for Research on Cancer (IARC), and is conducted within 4 Latin American countries: Mexico, Costa Rica, Colombia and Chile. Major aims of the project are the following: 1. To develop a multi-centric population-based case-control study on breast cancer in premenopausal women in several countries in Latin America with structured collection of individual, clinical, pathological information and biological specimens, according to strictly controlled protocols 2. To characterize, in these populations, the subtypes of premenopausal breast cancer on the basis of their molecular and pathological phenotypes 3. To improve the identification of specific endogenous/exogenous factors, and disentangle the interplay of these different factors with regard to breast tumor subtypes. 4. Provide advanced training, induce a structuring effect on the breast cancer research community in Latin America and influence the public health agenda regarding the management of breast cancer. The results of our study will be of utmost importance to understand the etiology of breast cancer in Latin America countries, and would provide important information on the role of modifiable exposures for breast cancer prevention.

CONDITIONS

Official Title

PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women

Who Can Participate

Age: 20Years - 45Years
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Woman between 20 and 45 years old
  • Woman less than 3 years older or younger than the case
  • Living in the area where the study is taking place for at least the past 3 years
  • Woman menstruated at least once in the past 12 months
  • Woman diagnosed with primary breast cancer by histopathological examination (only for cases)
Not Eligible

You will not qualify if you...

  • Woman receiving tumor treatment such as radiotherapy, chemotherapy, or anti-estrogens (except treatment for non-melanoma skin cancers)
  • Woman taking or has taken in the past 6 months medications like tamoxifen, raloxifene, toremifene, exemestane, letrozole, anastrozole, or megestrol
  • Woman suffering from chronic kidney failure
  • Woman having a condition that hinders adequate communication
  • Woman who is pregnant or nursing
  • Woman previously diagnosed with cancer (except non-melanoma skin cancers)
  • Any other reason for exclusion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 13 locations

1

Barretos Cancer Hospital

Barretos, Brazil

Completed

2

INC

Santiago, Independencia, Chile

Active, Not Recruiting

3

Hso-Crsco

Santiago, Peñalolén, Chile

Active, Not Recruiting

4

FALP

Santiago, Providencia, Chile

Active, Not Recruiting

5

Grupo Infección y Cáncer. Universidad de Antioquia

Medellín, Antioquia, Colombia, 050010

Actively Recruiting

6

International Hospital of Colombia

Bucaramanga, Bucaramanga, Colombia

Actively Recruiting

7

Facultad de Medicina, Universidad del Norte

Barranquilla, Colombia

Completed

8

Hospital Internacional de Colombia Fundacion Cardiovascular de Colombia

Bucaramanga, Colombia

Actively Recruiting

9

SENOSAMA foundation

Bucaramanga, Colombia

Actively Recruiting

10

Instituto de Oncología HematoOncologos

Cali, Colombia

Completed

11

Public Health University of Narino

Pasto, Colombia

Actively Recruiting

12

Agencia Costarricense de Investigaciones Biomédicas (ACIB)

San José, Provincia de San José, Costa Rica

Completed

13

Instituto Nacional de Salud Pública (INSP)

Cuernavaca, Morelos, Mexico, 69100

Completed

Loading map...

Research Team

S

Sabina Rinaldi, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women | DecenTrialz